Please login to the form below

Not currently logged in
Email:
Password:

Schering turns down Merck offer

Board says bid to create biggest German pharma firm 'significantly undervalues company'

 
Von Eschenbach in running for permanent FDA job
NHS trusts to face tougher ratings tests
 
Pharma news in brief
NHS news in brief
R&D news in brief
Schering has rejected a Ä14.6bn unsolicited takeover offer from rival Merck KGaA, increasing speculation that the German pharmaceutical sector is about to witness a bidding war.

As Schering's share price rose on investor speculation that Merck's bid would be sweetened, Schering chief executive Hubertus Erlen insisted that his company had no reason to join up with another.

Family-controlled Merck has confirmed that it made an offer of Ä77-a-share, a 15.4 per cent premium to Schering's closing share price on Friday (March 10).

ìGermany was once known as the pharmacy of the world,î said Jon Baumhauer, who represents the Merck family's 73 per cent stake on the group's board. ìThis deal would again bring us to the front of the international pharmaceutical industry.î

Erlen said the board had been informed of the offer at the weekend and had decided that it ìsignificantly undervalues the companyî.

ìWe looked at it and found that we had better prospects as an independent specialised company,î he said. ìShould the offer still come, we will not be able to recommend it to our shareholders.î

The head of Schering's supervisory board, Giuseppe Vita told reporters he expected a ìwhite knightî to launch a counter-bid, without naming any potential candidates.

A deal between Merck and Schering, two midsize companies, would create a significant European player, with annual sales of more than Ä11bn. Consolidation in the German pharma sector has been on hold since Hoechst merged with France's Rhone-Poulenc in 1998 to form Aventis in 1998.

Merck's move for Schering appears to be fuelled by its desire to boost its branded drug portfolio. While its best known product is cancer drug Erbitux, in recent years its chemicals division has overshadowed its pharmaceuticals unit, mainly thanks to sales of liquid crystals.

A merger with Schering would also beef up Merck's small presence in North America and Japan.

In November, Bernhard Scheuble stepped down as chief executive of Merck, after mounting tension with the company's owners over its future direction. He was replaced by Michael RÙmer, who vowed not to change Merck's strategy.

Schering is the world's biggest manufacturer of oral contraceptives, including the top-selling birth control pill, Yasmin. It also sells Betaferon for multiple sclerosis.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics